Regulatory reforms have speeded up new drug launches in a market notoriously slow at adopting treatments already in use elsewhere.
The Telegraph in the U.K. is reporting that the market buzz indicates that GSK is in talks with BioMarin, the rare disease drug outfit that has been snapping up programs in recent months.
The London-based drug giant lengthened its offer to HGS shareholder at the same $13-per-share price tag, holding less than 1% of the shares when the previous offer period expired Thursday, Reuters ' Ben Hirschler reported.
GlaxoSmithKline ($GSK) said it would and now it has. It extended its $2.6 billion hostile bid for shares of its partner Human Genome Sciences ($HGSI) by three weeks.
The GlaxoSmithKline-XenoPort drug won FDA approval to treat post-shingles nerve pain, a use that adds about 100,000 patients per year to its marketing pool. Whether the approval will mend fences between the two companies is another question.
Eli Lilly has discovered a new use for mobile apps--informing doctors about clinical trials for cancer drugs.
Bristol-Myers presents promising PD-1 data; Genentech boasts solid T-DM1 results; GSK aces pivotal studies; Ariad's ponatinib shines; Bayer's regorafenib delays stomach cancer; Zytiga impresses in prostate cancer; Aveo makes a PhIII case for tivozanib; Seattle Genetics expands its CD-30 horizons; ADCs arrive.
Roche may have to circle the wagons around its targeted melanoma drug Zelboraf. Positive data on two GlaxoSmithKline melanoma treatments have analysts predicting a quick assault on market share once they're approved, possibly next year.
Look out Roche. Because here comes GlaxoSmithKline touting upbeat results of two Phase III studies of the targeted drugs dabrafenib and trametinib in patients with metastatic melanoma.
Human Genome Sciences ($HGSI) won a court battle in its hostile takeover fight with partner GlaxoSmithKline ($GSK), but faces an ever-expanding and ugly war.